Intravenous Bisphosphonates for Postmenopausal Osteoporosis

Numerous clinical studies have shown bisphoshonates (BPs) to be useful and cost-effective options for the prevention of fractures and bone loss. The use of oral bisphoshonates is well established for the treatment of postmenopausal osteoporosis, but many of women complaint from gastrointestinal side effect or frequently dosed oral regimens. To improve upon the currently suboptimal level of therapeutic adherence in postmenopausal women who in fact, newer, longer-acting intravenous formulations of BPs has been approved for intermittent administration in postmenopausal women , and becomes an option for patients who cannot tolerate oral BPs or it was ineffective to increase bone density . This article proposed to review effectiveness and tolerability of these drugs in postmenopausal women with osteoporosis.